Targeted human papillomavirus vaccination for men who have sex with men

January 01, 0001

Targeted human papillomavirus vaccination for men who have sex with men

A vaccine targeting human papillomavirus (HPV) types 16 and 18, which are associated with 80% of anal cancers, is efficacious in men. High-risk populations such as men who have sex with men (MSM) might especially benefit from vaccination. The researcher from the USA aimed to estimate the cost-effectiveness of HPV vaccination of MSM in the USA.

In a scenario of HPV vaccination of MSM at 12 years of age without previous exposure to HPV, compared with no vaccination, vaccination cost US$15,290 per quality-adjusted life-year gained. In scenarios where MSM are vaccinated at 20 years or 26 years of age, after exposure to HPV infections, the cost-effectiveness ratios worsened, but were less than $50,000 per quality-adjusted life-year under most scenarios. For example, HPV vaccination of MSM at 26 years cost $37,830 per quality-adjusted life-year when previous exposure to all vaccine- targeted HPV types was assumed to be 50%. Outcomes were most sensitive to variations in anal cancer incidence, duration of vaccine protection, and HIV prevalence in MSM.

The researcher concluded: "HPV vaccination of MSM is likely to be a cost-effective intervention for the prevention of genital warts and anal cancer."

This does sound cost-effective.


For the full abstract, click here.

The Lancet Infectious Diseases published online 3 November 2010 © Elsevier Ltd 2010
Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Jane J Kim. Correspondence to: Jane Kim: [email protected]

Category: Y. Male Genital System, Breast. Keywords: papillomavarus, targeted, vaccination, men who have sex with men, cost-effectiveness modelling analysis, journal watch.
Synopsis edited by Dr Stephen Wilkinson, Melbourne, Australia. Posted on Global Family Doctor 3 December 2010

Pearls are an independent product of the Cochrane primary care group and are meant for educational use and not to guide clinical care.

COVID-19 Resources

WONCA webinars, journal links and more

WONCA position statements

WONCA statements on a variety of issues

PEARLS

577 Individual behavioural counselling helps people to quit smoking 575 Antioxidant vitamin and mineral supplements may be beneficial in age-related macular degeneration 574 Oral antifungals effective for toenail onychomycosis 570 Decision aids beneficial for people facing health treatment or screening decisions 569 Computer-generated reminders on paper benefit quality of care